Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
Vuh4YX4LYyPurqVG
Listen
